Related Experiment Video
Updated: Jul 7, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Effect of arotinolol on left ventricular function in patients with idiopathic dilated cardiomyopathy
Chao-mei Fan1, Hong Yang, Yi-shi Li
1Clinical Pharmacology Center, Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing. Fred_Fan2004@yahoo.com.cn
Insights
Long-term arotinolol treatment significantly improved left ventricular function and was safe in patients with idiopathic dilated cardiomyopathy (IDCM). This beta-blocker therapy offers a promising option for managing this heart condition.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Idiopathic dilated cardiomyopathy (IDCM) is a serious condition affecting heart muscle function.
- Effective long-term management strategies for IDCM are crucial for improving patient outcomes.
Purpose of the Study:
- To assess the efficacy and safety of prolonged arotinolol treatment in patients diagnosed with IDCM.
- To evaluate the impact of arotinolol on left ventricular function over a 12-month period.
Main Methods:
- Sixty-three IDCM patients received 12-month arotinolol therapy alongside standard congestive heart failure treatment.
- Left ventricular function was evaluated using the New York Heart Association functional class and two-dimensional echocardiography.
Main Results:
- Arotinolol treatment led to significant improvements in left ventricular systolic function.
- Key indicators such as left ventricular end-systolic dimension and ejection fraction showed marked positive changes.
- Left ventricular mass index also decreased, indicating potential reverse remodeling.
Conclusions:
- Twelve-month arotinolol treatment demonstrated a favorable impact on left ventricular function in IDCM patients.
- The study suggests arotinolol is a safe and well-tolerated therapeutic option for long-term use in this patient population.
Objective:
To evaluate the efficacy and safety of long-term treatment with arotinolol in patients with idiopathic dilated cardiomyopathy (IDCM).
Methods:
Sixty-three patients with IDCM were evaluated at baseline and after 12-month therapy with arotinolol. The conventional therapy for congestive heart failure was continued throughout the study with arotinolol as the only beta-blocker. Left ventricular function was assessed with the New York Heart Association functional class and two-dimensional echocardiography.
Results:
After 12-month arotinolol treatment, there was a significant improvement in left ventricular systolic function. Left ventricular end-systolic dimension significantly decreased from 59.52 +/- 8.83 mm to 50.89 +/- 8.17 mm (P < 0.001). Left ventricular ejection fraction significantly increased from 27.39% +/- 7.94% to 41.13% +/- 9.45% ( P < 0.001). Left ventricular mass index decreased from 150.47 +/- 42.42 g/m2 to 141.58 +/- 34.36 g/m2 (P < 0.01). No adverse events leading to premature discontinuation of study drug occurred.
Conclusion:
In this preliminary study, 12-month arotinolol treatment has a favorable effect on left ventricular function in patients with IDCM, and it is safe and well tolerated.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents
Aortic Regurgitation III: Medical Management
Cardiomyopathy V: Interprofessional Care

